Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 6,970 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma of the Breast Clear all
Completed Not applicable Interventional Results available

Effect of Increased Light Exposure on Fatigue in Breast Cancer

NCT00478257
View directory record Official record
Conditions
Breast Cancer
Interventions
bright white light, comparator red light treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography

NCT02306265
View directory record Official record
Conditions
Breast Cancer, Tumors, Breast, Cancer Screening
Interventions
FFDM, DBT
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Royal Oak, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery

NCT03324802
View directory record Official record
Conditions
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Breast Tissue Bioavailability of Topically Applied Limonene

NCT01459172
View directory record Official record
Conditions
Breast Cancer
Interventions
limonene containing massage oil
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

NCT00191672
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Gemcitabine, Paclitaxel, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Katy, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Self-management Interventions for Advanced Breast Cancer

NCT01927081
View directory record Official record
Conditions
Advanced Breast Cancer Stage IV
Interventions
discussion group, gentle exercise
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

NCT00003107
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 5, 2026, 9:38 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Fulvestrant
Drug
Lead sponsor
Nancy Chan, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

NCT00827177
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Treatment with ARQ 197 in combination with sorafenib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300
View directory record Official record
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 5, 2026, 9:38 AM EDT
Terminated Phase 2 Interventional Results available

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

NCT03248492
View directory record Official record
Conditions
Breast Cancer
Interventions
DS-8201a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 5, 2026, 9:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 5, 2026, 9:38 AM EDT
Active, not recruiting Not applicable Interventional

Oncology Episode Payment Model in Hawaii

NCT03523546
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Cancer Episode Payment Model (CEM)
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 5, 2026, 9:38 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545
View directory record Official record
Conditions
Human Mammary Carcinoma
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 5, 2026, 9:38 AM EDT
Not listed Phase 1 Interventional

A Study Evaluating MM-310 in Patients With Solid Tumors

NCT03076372
View directory record Official record
Conditions
Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Prostate Adenocarcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Soft Tissue Sarcoma
Interventions
MM-310
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 5, 2026, 9:38 AM EDT
Completed No phase listed Observational

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

NCT02370277
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 5, 2026, 9:38 AM EDT
Terminated Early Phase 1 Interventional

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

NCT03796273
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
Interventions
Best Practice, Ketoconazole
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

NCT06954337
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Usual practice pattern (UPP), Experimental: Enhanced Telehealth (ET)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 9:38 AM EDT
Suspended Phase 1 Interventional

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

NCT04120246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
Interventions
Alpha-tocopheryloxyacetic Acid, Trastuzumab
Drug · Biological
Lead sponsor
Veana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

NCT00327288
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
imexon, docetaxel
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

NCT02314156
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
West Hollywood, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 5, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

NCT02051751
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions
BYL719, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Fayetteville, Arkansas • Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 5, 2026, 9:38 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 9:38 AM EDT
Withdrawn Phase 2 Interventional

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

NCT05233696
View directory record Official record
Conditions
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer, PD-L1 Gene Mutation
Interventions
Nab-paclitaxel, Paclitaxel, Radiation Therapy, Pembrolizumab
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 5, 2026, 9:38 AM EDT